MKM Partners Reiterated Buy on Five Below (FIVE) Following Strong 4Q Results

Go back to MKM Partners Reiterated Buy on Five Below (FIVE) Following Strong 4Q Results

Pre-Open Stock Movers 03/23: (SQNM) (IONS) (AFFX) Higher; (SAGE) (SUNE) (KKD) Lower (more...)

March 23, 2016 9:35 AM EDT

Sage Therapeutics, Inc. (NASDAQ: SAGE) 13.3% LOWER; Kerrisdale Capital Short

SunEdison, Inc. (NASDAQ: SUNE) 12.8% LOWER; Stifel suspends rating, Axiom Capital cuts target to $0.22 following DIP discussions

Pieris Pharma (NASDAQ: PIRS) 11.7% HIGHER; reported Q4 EPS of ($0.07), versus ($0.21) reported last year. Revenue for the quarter came in at $2.14 million, versus $3.27 million reported last year.

Celator Pharmaceuticals, Inc.... More

After-Hours Stock Movers 03/22: (SCS) (AFFX) (DF) Higher; (KKD) (NKE) (RHT) Lower (more...)

March 22, 2016 6:10 PM EDT

Pieris Pharma (NASDAQ: PIRS) 11.7% HIGHER; reported Q4 EPS of ($0.07), versus ($0.21) reported last year. Revenue for the quarter came in at $2.14 million, versus $3.27 million reported last year.

Krispy Kreme Doughnuts (NYSE: KKD) 6.4% LOWER; reported Q4 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $130.4 million versus the consensus estimate of $133.02 million. Systemwide domestic same store sales rose 1.6%, including a 0.2% gain at Company shops; constant currency international franchise same store sales declined 7.1%. GUIDANCE: Krispy... More

Five Below (FIVE) Tops Q4 EPS by 1c

March 22, 2016 4:03 PM EDT

Five Below (NASDAQ: FIVE) reported Q4 EPS of $0.77, $0.01 better than the analyst estimate of $0.76. Revenue for the quarter came in at $326.4 million versus the consensus estimate of $323.74 million.

Comparable store sales increased 3.6%.

GUIDANCE:

Five Below sees Q1 2016 EPS of... More